nitrosoglutathione

Small moleculeexperimental

S-Nitrosoglutathione (GSNO) is an endogenous S-nitrosothiol (SNO) that plays a critical role in nitric oxide (NO) signaling and is a source of bioavailable NO. NO coexists in cells with SNOs that serve as endogenous NO carriers and donors. SNOs spontaneously release NO at different rates and can be powerful terminators of free radical chain propagation reactions, by reacting directly with ROO• radicals, yielding nitro derivatives as end products. NO is generated intracellularly by the nitric oxide synthase (NOS) family of enzymes: nNOS, eNOS and iNOS while the in vivo source of many of the SNOs is unknown. In oxygenated buffers, however, formation of SNOs is due to oxidation of NO to dinitrogen trioxide (N2O3). Some evidence suggests that both exogenous NO and endogenously derived NO from nitric oxide synthases can react with glutathione to form GSNO. — Wikipedia

Clinical trial activity

4 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Apr 30, 2019 (NCT03926741)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04619602Phase 1Oct 1, 2021Case Western Reserve University
NCT04528771Phase 1Oct 31, 2020Case Western Reserve University
NCT03999229Phase 1Jul 1, 2019Case Western Reserve University, National Heart, Lung, and Blood Institute (NHLBI)
NCT03926741Early Phase 1 (Phase 1)Apr 30, 2019Case Western Reserve University, National Heart, Lung, and Blood Institute (NHLBI)
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Case Western Reserve UniversityAcademic/Hospital4412019
National Heart, Lung, and Blood Institute (NHLBI)Government2012019
2 organizations
Page 1 / 1